HotSheets 2014  
Made possible by charitable contributions from Bayer, Astellas/Medivation, Takeda, Millennium, Pints for Prostates, Teva Oncology, Abbvie and Bavarian Nordic.

Click to Zoom

Our monthly newsletter, the HotSheet, highlights the latest in treatment strategies as well as emerging treatments. The HotSheet is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site. 

HotSheet Personal Subscriptions Now Available

If you are unable to attend chapter meetings to get the latest issue or prefer an original copy, we can deliver the newsletter right to your home or office. Download and print a subscription order form or order online.


January - March | April - June | July - September | October - December


January   | View Newsletter

February    | View Newsletter

March   | View Newsletter

  • New Drug Boosts Prostate Cancer Survival
  • Low Response to Da Vinci Surgery Survey
  • IMRT Feasible for Lymph Node Metastases
  • Prostate Cancer Incidence after Termination of a Population-Based PSA-Screening Program
  • Death Rate from Metastatic Prostate Cancer at Diagnosis Has Not Improved over 20 Years
  • Doc Moyad’s “No Bogus Science” Column - “Magnesium Is Good for Cardiovascular Health” 
  • Index of Articles Published in 2013 HotSheets
  • Doctor Chodak’s Bottom Line
  • Coffee Consumption & Risk of Non-Aggressive, Aggressive & Fatal Prostate Cancer
  • Qigong Improves Prostate Cancer Fatigue
  • Pain Drugs Used During Surgery & Outcome
  • Potential Biological Factor to Explains Racial Disparities in Prostate Cancer
  • Xtandi after Relapse to Docetaxel & Zytiga
  • MRI and CT PET Imaging for Preoperative Pelvic Node Staging in Prostate Cancer
  • Use of Statins and Risk of Death in Patients with Prostate Cancer
  • Doc Moyad’s “No Bogus Science” Column - "Multivitamins – the Piñata of Supplements"
  • Zytiga + Prednisone vs. Prednisone Alone in Chemotherapy-Naïve Men with CRPC
  • Post-RP Pathology in Candidates for AS
  • RT Plus ADT Benefit Confirmed in Men with High-risk Prostate Cancer
  • Long-term Safety of Radium-233 Confirmed in Advanced Castrate Resistant Prostate Cancer
  • Enzalutamide before Chemotherapy Slows Disease Progression in Metastatic Disease
  • Clinical Variables and Response to Abiraterone
  • Media Storm Caused by Deaths in Phase 2 Trial of PSMA Antibody Drug Conjugate
  • New Agent Misses Mark in Advanced Cancer
  • Prostate Health Index May Identify Men on Active Surveillance Requiring Treatment
  • Doc Moyad's "No Bogus Science" Column – "Testosterone, Exercise or Both?"
  • FDA Now Investigating Cardiovascular Risks of Testosterone Supplementation
  • Prolaris Modifies Physician Decision-Making
  • Doctor Chodak's Bottom Line

April   | View Newsletter

May   | View Newsletter

June   | View Newsletter

  • Surgery Better than Watchful Waiting for Younger Prostate Cancer Patients
  • How Selenium and Vitamin E Increase Prostate Cancer Risk
  • Toxicity Limits Potential Use of Less Expensive form of Prostate Cancer Treatment
  • Stress, Lack of Social Support Linked to Prostate Cancer Mortality
  • New Genes for Familial Prostate Cancer
  • Robot-Assisted Prostate Surgery Offers Better Cancer Control (or Does It?)
  • Doc Moyad’s “No Bogus Science” Column – “Limit your sugar intake, says the WHO”
  • Gleason Inflation—1998 to 2011
  • Modified Gleason Grade in PLCO Trial
  • Doctor Chodak’s Bottom Line
  • New NCCN Guideline Seeks 'Middle Ground' on PSA Testing
  • ADT Offers No Survival Advantage as Primary Treatment for Localized Prostate Cancer
  • PSA Screening Tests Down
  • HIFU Salvage for Recurrent Prostate Cancer That Progresses Following RT
  • Salvage Prostatectomy Vs Cryotherapy for Recurrent Prostate Cancer Following RT
  • Relative Value of Race, Family History and PSA as Indicators for Early Screening
  • Doc Moyad’s "No Bogus Science" Column – "Predicting Vitamin D Levels from BMI"
  • Combination and Sequencing: The Future of Immunotherapy in Prostate Cancer
  • New Biomarker Could Help Predict Resistance to Xtandi in Prostate Cancer
  • Doctor Chodak's Bottom Line
  • Can Imaging Replace Biopsy for Some Prostate Cancer?
  • Longest Prostate Cancer Active Surveillance Study Promising
  • Quarter of AS Participants Abandon Approach
  • Defining Very-High-Risk Prostate Cancer
  • Predicting the Laterality of Prostate Cancer for Selecting Candidates for Focal Therapy
  • FDA Fast-Tracks OncoGenex Drug for CRPC
  • Doc Moyad’s “No Bogus Science” Column – “Artificial Sweeteners and Weight Loss”
  • No Increased Risk of Myelodysplastic Syndromes from External Beam Radiotherapy
  • Potency after Prostate Brachytherapy 6 PSA Doubling-Time Calculator for iPhone
  • Hypofractionated Radiotherapy & Toxicity
  • Doctor Chodak’s Bottom Line

July   | View Newsletter

August   | View Newsletter

September   | View Newsletter

  • Delaying ADT Does No Harm in Prostate Cancer
  • Chemohormonal Treatment May Be Better in Newly Diagnosed Metastatic Prostate Cancer
  • Low-Risk Prostate Cancer with Standard Biopsy May Be More Aggressive with Targeted Biopsy
  • Early Return of Urinary Continence Following Robot-Assisted Laparoscopic Prostatectomy
  • Predominant Gleason Pattern 4 Is Associated with Low Serum Testosterone Levels
  • Phi Test Added to NCCN Recommendations
  • Orteronel Delays Disease Progression
  • Doc Moyad’s “No Bogus Science” Column – “Did You Know the U.S. Ranks #1 in Obesity?”
  • Dominant/Index Lesion in Prostate Cancer
  • Prolaris® Test Validated – Triumph or Worry?
  • Nadir Testosterone on ADT Predicts Time to Castrate-Resistant Disease Progression
  • Doctor Chodak’s Bottom Line
  • New Radiotracer for Prostate Cancer
  • US Adoption of Active Surveillance Is Slow
  • Sexual Roles & QOL in Gay Men after Prostate Cancer
  • Aggressive Vs. Nonaggressive Treatment of Men with Localized Prostate Cancer with High-Risk Features
  • 3T Multiparametric MRI vs. the Partin Tables
  • Overtreatment Concerns Using ASCO/ASTRO Guidelines with Post-prostatectomy Radiation Treatment
  • Impact of NADiA ProsVue on Secondary Treatment Decisions after Radical Prostatectomy
  • Low Detectable PSA after Radical Prostatectomy
  • Doc Moyad’s “No Bogus Science” Column – “Nothing New with Vitamin C & E Supplements!”
  • PSA Flare vs. Disease Progression with Docetaxel
  • Insurance Status & Racial Disparities in Treatment
  • Vasectomy & Prostate Cancer
  • Depression May Keep Some Men from Fighting Prostate Cancer
  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
  • Health Care Costs for Patients Receiving ADT : Treatment & Adverse Events
  • Optimization of Prostate Biopsies
  • Factors Associated with Stopping AS in Men with Localized Prostate Cancer
  • Elevated Alkaline Phosphatase Velocity, Overall Survival and Risk of Bone Mets
  • Open Versus Robotic Prostatectomy and Risk of Positive Margins
  • CRPC & Overall Survival When ADT Is Given for PSA Recurrence after Radical Prostatectomy
  • FDA Panel Recommends Against Approval of HIFU for Early Prostate Cancer
  • Can the Best Course of Action after RP Be Determined by Genomic Testing?
  • Doc Moyad’s “No Bogus Science” Column – “Flu Shots and Cardiovascular Events”
  • Doctor Chodak’s Bottom Line

October   | View Newsletter

November   | View Newsletter

December   | View Newsletter

  • Doctors Drive Treatment Choice in Men Diagnosed with Prostate Cancer
  • ADT Heads List of Therapies in New Prostate Cancer Guideline
  • Results of the COMET-1 Phase 3 Trial of Cabozantinib in Men with mCRPC
  • Observer Reproducibility in Interpreting PET/CT Examinations in Men with BCR
  • Number of Cores at 1st Biopsy & the Need for Confirmatory Biopsy in Active Surveillance
  • Doc Moyad's "No Bogus Science" Column – "Which Diet Is the Best for You?"
  • A Treatment Option for Advanced Prostate Cancer that Has Spread to the Bones
  • Variation in Treatment Vs. Life Expectancy in Men with Early-Stage Prostate Cancer
  • Doctor Chodak's Bottom Line
  • FDA Approves New Use of XTANDI® for mCRPC Patients Prior to Chemotherapy
  • Overall Survival with ZYTIGA® Plus Prednisone After 49 Months of Follow-Up
  • PSA Bounce after Radiotherapy May Be Associated with Outcomes
  • Radical Prostatectomy Rates Rising
  • Can We Expand Active Surveillance Criteria to Biopsy Gleason 3+4=7 Prostate Cancer?
  • 89Zr-huJ591 Immuno-PET Imaging in Men with Advanced Metastatic Prostate Cancer
  • Genetic Stratification of Gleason 7 Cancers
  • Doc Moyad's "No Bogus Science" Column – "Willow Bark Extract (salicin) vs. Aspirin
  • Q&A Interview on Cancer Immunotherapy in Prostate Cancer with Dr. Neal Shore
  • Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non- Metastatic Castrate Resistant Prostate Cancer
  • Doctor Chodak's Bottom Line

Facebook -  Twitter -  LinkedIn - Inspire prostate cancer discussions – 

Contact Us | Privacy Policy | Terms & Conditions | Disclaimer   

Copyright © 2005-2017 Us TOO International, Inc.
Designed and hosted by ACCESS Medical Group, Ltd.